Literature DB >> 16920932

Requirement for CD70 in CD4+ Th cell-dependent and innate receptor-mediated CD8+ T cell priming.

Vadim Y Taraban1, Tania F Rowley, David F Tough, Aymen Al-Shamkhani.   

Abstract

Dendritic cell (DC) conditioning by CD4+ T cells, or via engagement of innate receptors, is thought to be essential for CD8+ T cell priming. However, the molecular features that distinguish a conditioned DC from an unconditioned DC are poorly defined. In this study, we investigate the role of CD70, a member of the TNF superfamily that is expressed on activated DC, in CD4+ Th-dependent and -independent CD8+ T cell responses. We demonstrate that CD70 is required for CD4+ T cell-dependent priming of CD8+ T cells as well as priming mediated by the viral signature, dsRNA. Accordingly, mice that were subjected to CD70 blockade during the primary response fail to generate a memory CD8+ T cell response. Furthermore, we find that CD70 is dispensable for CD4+ T cell expansion and help for B cells, thus suggesting a direct role for CD70 in CD8+ T cell priming. Our results show that the innate and adaptive (CD4+ T cells) arms of the immune system use a common signaling pathway in driving CD8+ T cell responses and suggest that expression of CD70 on DC represents the hallmark of conditioned DC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920932     DOI: 10.4049/jimmunol.177.5.2969

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses.

Authors:  Katherine E Van Deusen; Rohan Rajapakse; Timothy N J Bullock
Journal:  J Leukoc Biol       Date:  2009-12-01       Impact factor: 4.962

2.  CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.

Authors:  Han Dong; Nathan A Franklin; Shane B Ritchea; Hideo Yagita; Martin J Glennie; Timothy N J Bullock
Journal:  Eur J Immunol       Date:  2015-11-06       Impact factor: 5.532

3.  Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity.

Authors:  Jennifer A McWilliams; Phillip J Sanchez; Catherine Haluszczak; Laurent Gapin; Ross M Kedl
Journal:  Vaccine       Date:  2009-12-06       Impact factor: 3.641

Review 4.  Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies.

Authors:  Xue Han; Matthew D Vesely
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-20       Impact factor: 6.813

Review 5.  Immunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells.

Authors:  Jessica Bourque; Daniel Hawiger
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

6.  The CD4⁺ T-cell help signal is transmitted from APC to CD8⁺ T-cells via CD27-CD70 interactions.

Authors:  Sonia Feau; Zacarias Garcia; Ramon Arens; Hideo Yagita; Jannie Borst; Stephen P Schoenberger
Journal:  Nat Commun       Date:  2012-07-10       Impact factor: 14.919

Review 7.  Memories that last forever: strategies for optimizing vaccine T-cell memory.

Authors:  Jeffrey D Ahlers; Igor M Belyakov
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

Review 8.  The role of TNF superfamily members in T-cell function and diseases.

Authors:  Michael Croft
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

9.  Dual function of CD70 in viral infection: modulator of early cytokine responses and activator of adaptive responses.

Authors:  Atef Allam; Melissa Swiecki; William Vermi; Jonathan D Ashwell; Marco Colonna
Journal:  J Immunol       Date:  2014-06-09       Impact factor: 5.422

10.  CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.

Authors:  Anna Wasiuk; James Testa; Jeff Weidlick; Crystal Sisson; Laura Vitale; Jenifer Widger; Andrea Crocker; Lawrence J Thomas; Joel Goldstein; Henry C Marsh; Tibor Keler; Li-Zhen He
Journal:  J Immunol       Date:  2017-11-06       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.